Table 2 Baseline patient characteristics
| Â | Patients with uterine fibroids (n=17) | Endometriosis | ||||
|---|---|---|---|---|---|---|
| Â | Â | Control (n=14) | Dienogest 2 mg (n=13) | LA 3.75 mg (n=16) | ||
| Â | baseline | baseline | baseline | preoperation | baseline | preoperation |
Age (years, mean ± SD | 44.2 ± 6.8 | 34.9 ± 8.1 | 34.3 ± 5.7 | 37.5 ± 7.2 | ||
Duration of drug administration | - | - | 21.6 ± 11.5 | 12.6 ± 2.8 | ||
Pelvic pain VAS (mm, mean ± SD) | 23.8 ± 18.2 | 53.1 ± 29.9 | 46.2 ± 22.6a | 20.6 ± 15.1b | 56.3 ± 41.0ab | 21.1 ± 18.0b |
CA-125 (U/ml, mean ± SD) | 33.1 ± 20.4 | 60.3 ± 34.1 | 60.6 ± 35.8 | 34.8 ± 14.9c | 52.9 ± 42.8 | 34.9 ± 20.8 |
r-AFS stage (n,%) | Â | Â | Â | Â | Â | Â |
I: minimal | 10 (58%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
II: mild | 3 (18%) | 0 (0%) | 0 (0%) | 2 (13%) | ||
III: moderate | 4 (24%) | 5 (36%) | 8 (62%) | 9 (56%) | ||
IV: severe | 0 (0%) | 9 (64%) | 5 (38%) | 5 (31%) | ||